Navigation Links
Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government
Date:7/22/2009

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions, and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, while the Company has completed shipment of the initial order of raxibacumab to the U.S. Strategic National Stockpile, the Company will continue to face risks related to FDA's approval of the Company's Biologics License Application for raxibacumab. If the Company is unable to meet requirements associated with the raxibacumab contract, future revenues from the sale of raxibacumab to the U.S. Government will not occur. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or oth
'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... German . ... have demonstrated a new kind of building block for ... chips could be based on three-dimensional arrangements of nanometer-scale ... of the semiconductor industry CMOS fabrication of silicon ... collaborators at the University of Notre Dame are exploring ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... to kill nematodes. Nematodes are microscopic parasitic roundworms, ... water, and inside other plants and animals. Nematicides ... volatility or other properties promoting migration through the ... more than 1,000 plant-parasitic nematodes. With more than ...
(Date:9/30/2014)... -- CORD:USE Cord Blood Bank – www.corduse.com ... into an Equity and Exclusive Services Agreement with Tianhe Stem ... patented technologies for the isolation of human cord blood-derived ... performing Phase I/II clinical trials in China ... Tianhe,s Stem Cell Educator Therapy showing that the therapy ...
(Date:9/30/2014)... Md., Sept. 30, 2014 BioHealth Innovation, ... commercializing market-relevant biohealth innovations and increasing access to early-stage ... today that venture capitalist, Tania Fernandez , Ph.D., ... Dr. Fernandez will be a member of the management ... provide up to $50 million in seed and early-stage ...
Breaking Biology Technology:A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... 4 The Arcas Group, a leading ... Terwindt, MBA as Executive Vice President. He will assume ... previously served as President of Imedex, Inc."Stefan is an ... skills to our company," said Founder and President Jan ...
... Blakely & Company, LLC, a Boston-based life science investment ... III has joined the firm as senior advisor. ... firm on internal and client-related activities including private equity ... particular focus on medical device transactions. "We are ...
... Pharma Limited ("Circ Pharma") and,Elan Corporation plc ("Elan") ... Agreement to develop a chronotherapeutic formulation of Tramadol,for ... , The product incorporates ... dosing. Circ,s technology provides for,minimized delivery to the ...
Cached Biology Technology:The Arcas Group Appoints Executive Vice President 2Venture Capital Veteran John Brooks Joins Life Science Investment Bank Johnston Blakely & Company 2Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc 2
(Date:9/30/2014)... German . , ... situations such as exposure to predators. Researchers from the ... long-term study on different populations of great tits that ... temperature. High metabolic rates and low temperatures were associated ... were more likely to approach potential predators. , The ...
(Date:9/30/2014)... 2014) People who suffer from asthma may think ... their asthma besides properly taking medications and avoiding allergic ... the Annals of Allergy, Asthma and Immunology , ... Asthma and Immunology (ACAAI), asthma sufferers can learn lessons ... woman described in the Annals article improved her asthma ...
(Date:9/29/2014)... confirms that the exposure to tar tended to be ... cigarettes. Similarly, exposure to nicotine tended to be ... of cigarette in several countries around the world. Previous ... chemicals in the smoke of these cigarettes are lower ... of chemicals in the smoke are not necessarily linked ...
Breaking Biology News(10 mins):Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2Slim cigarette smokers not exposed to more harmful chemicals 2
... Labs) have succeeded in combining two forms of medical ... are particularly useful for cancer research. The two techniques ... can be performed simultaneously and they give a higher ... is known as the VECTor (Versatile Emission Computed Tomography) ...
... Spanish . The University of Navarra, together ... taking part in a project to discover the origin of myelodysplasia, ... work, patients from 19 hospitals in the north of Spain ... as from England, Italy, Sweden and Germany. The aim of ...
... St. Louis, MO, June 1, 2010 Making food ... diet according to a new study comparing the nutritional content ... in the June issue of the Journal of the ... 2,000-calorie diet consisting entirely of advertised foods would contain 25 ...
Cached Biology News:TU Delft and MI Labs merge PET and SPECT biomedical imaging techniques and increase resolution 2TV food advertisements promote imbalanced diets 2
Fingerprinting II database sharing tools is an optional module for the Fingerprinting II Basic software package that enables peer-to-peer data exchange over the internet and provides external databas...
... Fingerprinting II Informatix ... an optional module ... component analysis, multidimensional ... and MANOVA, and ...
Fingerprinting II comparative quantification and polymorphism analysis is an optional module that adds comparative quantification and polymorphism analysis functions to the Fingerprinting II Basic so...
... instrument is the most advanced thermal cycler ... thermal performance, the Dyad also boasts graphical ... point-and-click navigation via touch pad or mouse. ... and economically expanded to a four-bay system ...
Biology Products: